



LANE, NANCY E. Director and Endowed Professor, Aging Center, Medicine and Rheumatology, University of California at Davis Medical Center, Sacramento, California

Place of Birth: Los Angeles, California, USA

Education/Training/Positions: BS, University of California, Davis, Biochemistry, 1976; MD, University of California, San Francisco (UCSF), 1980; Residency in Medicine, San Francisco, CA, 1980-1983; Fellowship as Clinical Fellow in Rheumatology, Stanford University Medical Center, Stanford, CA, 1983-1985; Diplomate, American Board of Internal Medicine, 1983; Diplomate, Subspecialty Board of Rheumatology, 1986; Assistant Professor of Medicine and Rheumatology, UCSF, 1990-1995; Associate Professor of Medicine, UCSF, 1996-2004;

Endowed Professor of Aging, Director Center for Aging, UC Davis School of Medicine, 2005-present

Honors/Awards: Department of Biochemistry Citation, Phi Kappa Phi, University of California, 1976; Western Region, Merck Rheumatology Fellow Award, 1984; Subspecialty Board for Rheumatology, American Board of Internal Medicine, 1984, 1987; Nominated and elected, Executive Leadership in Academic Medicine, 1997; Marilyn S. Singleton Scholarship for Women Leadership in Academic Medicine, 1997; Endowed Professor in Aging, UC Davis, 2004; Ira Goldstein Memorial Lecture, NYU University, March 2007; Honored by ASBMR for USBJD Presidency, 2007; Finalist, Marion Spencer Fay Award, National Board for Women in Medicine and Leadership Institute for Drexel University College of Medicine, 2007-present; Inducted, San Mateo County Women's Hall of Fame, 2008; UC Davis School of Medicine Dean's Award for Research Mentoring, 2008

Editorial Duties/Peer Review Panels: Editorial Boards: *Arthritis and Rheumatism* 1998-present; *Osteoporosis International*, 1999-present; *Journal of Rheumatology*, 1995-present; *Journal of Clinical Rheumatology*, 1995-present; *Journal of Bone and Mineral Research*, 2004-present; *Nature Clinical Practice Rheumatology*, 2007-present; Faculty 1000 of Medicine, 1999-2001; Section Editor, *Osteoporosis Current Rheumatology Reports*, 2002-2007; *Journal of Musculoskeletal Medicine*, 1997-present; Associate Editor: *Arthritis Research and Therapy*, 2007-present; ASBMR *Primer of the Metabolic Bone Diseases*, Editions 4 and 5; Co-Editor, *Arthritis and Rheumatism*, 2005-present; Peer Review Panels: NIAMS Clinical Trial Review, 1994; External Grant Reviewer: Arthritis and Rheumatism Council for Great Britain; Wellcome Trust; Kennedy Institute, 1995-2008; Grant Reviewer: Department of Defense, 1996; NIH/NIAMS Orthopaedic Study Section, 1997-2001; DSMB member, R01AG18397, 2001-present; Chairperson, NIAMS Centers of Excellence in MS Diseases Core Centers, 2006; Grant Reviewer: NIH NIAMS K23 Loan Repayment, and R03 Awards, 2004-2008; NIAMS Go Grand Ad-hoc Study Section, 2009

Professional Societies: ASBMR; Association of Osteobiology; Association of American Physicians; President U.S. Bone and Joint Decade Board of Directors, 2005-2007; ASBMR Representative, Executive Board of Directors, U.S. Bone and Joint Decade, 2005-2009; Co-chair, U.S. Board Joint Decade Organizing Committee, 2009

Current Research: Cell biology of glucocorticoid induced osteoporosis; effects of bone active agents on the localized and whole bone material properties in a rat model of osteoporosis; the epidemiology and genetics of osteoarthritis of the hip and knee; risk factors for osteoporotic fractures; novel therapies to treat osteoporosis

Statement of Interest: Briefly outlined below are my qualifications for the position of ASBMR Councilor. After graduating from the University of California at Davis with a Bachelor's of Science degree in Biochemistry, I completed Medical School at the University of California at San Francisco, Internal Medicine Residency at Mt Zion/UCSF and my rheumatology fellowship at Stanford University Medical Center. During my continuous 20-year involvement in ASBMR, I have been an active participant in a number of committees and other assignments including serving as a member of the In Vivo Bone Research Group from 1994 to present, a member of the abstract selection committee (2002-2004, 2007), full member of the scientific policy committee (2003-2006), ASBMR executive board representative to the U.S. Bone and Joint Decade (2006-2009), Invited Speaker for annual meeting for Grant Writing tips (2003, 2004 and 2005), Inflammatory Bone Loss (2005 and 2006), and Glucocorticoid-induced osteoporosis (2009), In vivo working group invited speaker (2000 and 2009), and moderator of a number of scientific sessions (1994, 2007, 2008 and 2009), and have been a member of ASBMR special task forces for Mentorship Awards and the Harold Frost Young Investigator Awards (2004 and 2007).

The ASBMR Board supported me as a representative to the education and research committee of the USBJD in 2004-2005. The purpose of that committee was to develop a plan to address how to increase the number of clinical investigators performing musculoskeletal research in the US. Working on this subcommittee, with members of the ASBMR and ORS, we initiated the Young Investigators Workshop. As the chair of this USBJD task force, we assembled a committed faculty of approximately 15, senior investigators throughout the United States and Canada and have now had approximately 7 workshops (2 each year: one in the fall and one in the spring), with nearly 90 participants and almost \$25 million in grant funding from peer-reviewed organizations has been obtained. This program has required that I participate in fund raising and we have obtained funding to support this work from the NIH (an R13 and an U13), supporting organizations of the USBJD (including the ASBMR) and pharmaceutical industry support. In addition, the ASBMR supported my nomination as President of the Board for the United States Bone and Joint Decade (2005-2007), and Past-President year (2007-2008), and co-ASBMR representative 2008-2009. During my tenure as the ASBMR representative to the Board of the USBJD, I have been able to further the ASBMR mission of

increasing research in bone diseases, train young investigators in grant writing through USBJD sponsored Young Investigator Grant Writing Workshops, support the development of a musculoskeletal subject examination in medical schools and raise awareness of bone diseases through the development of an action plan for osteoporosis to increase the dissemination of the Surgeon General's Report on Osteoporosis and assisting in the development of the Rare Bone Disease Coalition. These efforts demonstrate my successful experience running committees, working as a team player and completing the mission of the group.

My current position is Director of the Center for Healthy Aging at U.C. Davis Medical Center and Professor of Medicine and Rheumatology. My job has allowed me to recruit and mentor a number of junior faculty in the field of bone metabolism. My laboratory research in bone quality is NIH funded and our work is routinely presented at the annual ASBMR meeting. In addition, our research group has always engaged national and international collaborations with other bone researchers and this has provided me with a solid understanding of the international nature of the ASBMR.

In summary, this statement explains my interest and supports my qualifications for a position on the ASBMR Council. My long standing work in the field of bone metabolism, experience with professional society boards, my deep commitment to working within the ASBMR to promote and grow the organization and young investigators in the field, positions me well to be an effective councilor.

Disclosures: Amgen 2, 3; Eli Lilly and Co. 3; NordicBiosciences/Novartis 1; Pfizer 1; Proctor and Gamble 1

The following numerical key was used to characterize the potential conflicts of interest listed in the "Disclosures" section above.

1. *research grants or financial support from commercial entities*
2. *consultant or member of advisory board to a commercial entity*
3. *participant in a speakers bureau*
4. *employment or executive positions in pharmaceutical, medical device, or diagnostic companies*
5. *stock holdings in pharmaceutical, medical device, or diagnostic companies*
6. *any other situation or transaction in relation to the ASBMR in which a formal role or interest exists (e.g., candidate is a member of another bone-related organization's board, or committee, or serves on its journal, etc.)*